Your shopping cart is currently empty

AG 045572 is a potent GnRH receptor antagonist that inhibits the GnRH receptor in humans and rats with Ki values of 6.0 nM and 3.8 nM, respectively.AG 045572 is metabolized by CYP3A and inhibits testosterone.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $40 | In Stock | In Stock | |
| 5 mg | $98 | In Stock | In Stock | |
| 10 mg | $158 | In Stock | In Stock | |
| 25 mg | $318 | In Stock | In Stock | |
| 50 mg | $497 | In Stock | In Stock | |
| 100 mg | $723 | In Stock | In Stock | |
| 200 mg | $998 | - | In Stock |
| Description | AG 045572 is a potent GnRH receptor antagonist that inhibits the GnRH receptor in humans and rats with Ki values of 6.0 nM and 3.8 nM, respectively.AG 045572 is metabolized by CYP3A and inhibits testosterone. |
| Targets&IC50 | GnRHR (rat):3.8 nM(ki), GnRHR (human):6.0 nM(ki) |
| In vitro | AG 045572 (10 μM, 40 min, for human liver microsomes; 10 μM, 10 min, for male rat liver microsomes; 1 μM, 10 min, for female rat liver microsomes) is metabolized by CYP3A in both rats and humans. The Km values in male and female human and female rat liver microsomes and expressed CYP3A4 and CYP3A5 were similar (0.39, 0.27, 0.28, 0.25, and 0.26 μM, respectively), while the Km values in male rat liver microsomes were 1.5 μM, indicating that AG-045572 is metabolized by different CYP3A isoenzymes in male and female rats.[1] |
| In vivo | AG 045572 (10 mg/kg (i.v.) or 20 mg/kg (p.o.), one time) in intact male rats showed moderate T1/2, CL and Vss but low oral bioavailability, with The bioavailability is higher in female rats (24%), and the pharmacokinetics in castrated male rats are similar to those in female rats.[1] The pharmacokinetics of AG 045572 (40 mg/kg; i.m.; twice a day for 3 days) in intact male rats changed, and the parameters were similar to those in female and castrated male rats.[1] |
| Molecular Weight | 491.62 |
| Formula | C30H37NO5 |
| Cas No. | 263847-55-8 |
| Smiles | CC1(C)C=2C(=CC(C)=C(CC=3OC(C(NC4=C(OC)C=C(OC)C=C4OC)=O)=CC3)C2)C(C)(C)CC1 |
| Relative Density. | no data available |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 55 mg/mL (111.88 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.07 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.